Edition:
United Kingdom

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

3.02USD
23 May 2018
Change (% chg)

$-0.03 (-0.98%)
Prev Close
$3.05
Open
$3.04
Day's High
$3.04
Day's Low
$3.01
Volume
7,753
Avg. Vol
13,914
52-wk High
$4.09
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Evoke Pharma Posts Loss Of $0.13 Per Share in Q1
Monday, 14 May 2018 

May 14 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REPORTS FIRST QUARTER 2018 RESULTS AND HIGHLIGHTS.Q1 LOSS PER SHARE $0.13.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.NDA SUBMISSION FOR GIMOT ON TRACK FOR Q2 OF 2018.INCLUDED IN NET LOSS FOR Q1 WAS A GAIN OF ABOUT $433,000 DUE TO CHANGE IN FAIR VALUE OF WARRANT LIABILITY.  Full Article

Evoke Announces Agreement With Mallinckrodt To Amend Milestone Payments
Monday, 26 Mar 2018 

March 26 (Reuters) - Evoke Pharma Inc ::EVOKE ANNOUNCES AGREEMENT WITH MALLINCKRODT TO AMEND MILESTONE PAYMENTS.‍HAS AMENDED CO'S AGREEMENT WITH MALLINCKRODT, ARD INC. TO DEFER DEVELOPMENT AND APPROVAL MILESTONE PAYMENTS FOR GIMOTI​.AMENDED AGREEMENT DEFERS AMOUNT AND TIMING OF TWO MILESTONE PAYMENTS​.‍AMENDED AGREEMENT DEFERS AMOUNT AND TIMING OF TWO MILESTONE PAYMENTS DUE UPON U.S. FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION​.EVOKE PHARMA - HAVE IMPROVED CASH RUNWAY TO JANUARY OF NEXT YEAR AND REMAIN ON TRACK TO SUBMIT GIMOTI NDA NEXT QUARTER.  Full Article

Evoke Pharma reports Q3 loss per share $0.34
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Evoke Pharma Inc ::Evoke Pharma reports third quarter 2017 results and highlights.Q3 loss per share $0.34.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma signs commercial agreement with Thermo Fisher Scientific
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Evoke Pharma Inc ::Signs commercial agreement with Thermo Fisher Scientific.Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti​.Under five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke's potential commercial efforts​.  Full Article

Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Evoke Pharma Inc ::Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™.Evoke Pharma- co will submit a 505(b)(2) NDA with a selected gimoti dose to the U.S. FDA in Q1 of 2018​.Evoke Pharma Inc- ‍relative to safety, all gimoti doses were well‑tolerated.  Full Article

Evoke Pharma announces proposed public offering of common stock
Wednesday, 15 Feb 2017 

Evoke Pharma Inc : Evoke Pharma announces proposed public offering of common stock . Evoke Pharma Inc says intends to offer and sell shares of its common stock in a "firm commitment" underwritten public offering .Evoke Pharma - Intends to use net proceeds from offering to fund clinical development, pre-approval and pre-commercialization activities for Gimoti.  Full Article

FDA exempts Evoke from requirement for human factor validation study
Wednesday, 15 Feb 2017 

Evoke Pharma Inc : FDA exempts Evoke from requirement for human factor validation study . Evoke Pharma Inc- received a letter from FDA exempting Gimoti™ from a human factors validation study requirement prior to submission of NDA . Evoke Pharma Inc- In their written response, FDA determined that an HF validation study is not needed at this time for Gimoti .Evoke Pharma Inc- Intend to pursue an NDA submission by end of year for Gimoti.  Full Article

Evoke Pharma Q2 loss per share $0.41
Monday, 15 Aug 2016 

Evoke Pharma Inc : Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.41.  Full Article

Evoke Pharma Q2 shr loss $0.41
Monday, 15 Aug 2016 

Evoke Pharma Inc : Evoke pharma reports second quarter 2016 results . Q2 shr loss $0.41 . Q2 shr view $-0.43 -- thomson reuters i/b/e/s .Evoke Pharma says "we will continue to work with fda to pursue a path to approval of gimoti".  Full Article

Evoke Pharma announces $10 million registered direct offering
Friday, 29 Jul 2016 

Evoke Pharma Inc : Evoke Pharma announces $10 million registered direct offering priced at-the-market .Says will issue common stock at a purchase price of $3.0825 per share.  Full Article

BRIEF-Evoke Pharma Granted Gender Specific Patent For Gimoti In Mexico

* EVOKE GRANTED GENDER SPECIFIC PATENT FOR GIMOTI™ IN MEXICO Source text for Eikon: Further company coverage: